XML 18 R4.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
EXPENSES    
General and administrative $ 6,095,607 $ 10,274,600
Research and development 5,209,250 4,486,120
Total expenses 11,304,857 14,760,720
LOSS FROM OPERATIONS (11,304,857) (14,760,720)
OTHER EXPENSE (INCOME), NET    
Gain on change in fair value of warrant liabilities (2,035,469) (907,203)
Interest expense, net 1,524,722 34,397
Loss on voluntary conversion of convertible debt 1,077,287
Loss on debt extinguishment 625,653
Loss on fixed asset disposal 21,747
Other income, net (38,994)
Total other expense (income), net 1,174,946 (872,806)
LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES (12,479,803) (13,887,914)
(BENEFIT) PROVISION FOR INCOME TAXES (4,793) 6,548
NET LOSS FROM CONTINUING OPERATIONS (12,475,010) (13,894,462)
DISCONTINUED OPERATIONS    
Loss from discontinued operations, net of tax (683,008) (7,140,181)
Loss on disposal of discontinued operations, net of tax (602,232)
LOSS FROM DISCONTINUED OPERATIONS (1,285,240) (7,140,181)
Net loss (13,760,250) (21,034,643)
Net loss attributable to non-controlling interest from discontinued operations (343,038) (2,394,100)
Net loss attributable to Qualigen Therapeutics, Inc. $ (13,417,212) $ (18,640,543)
Net loss per common share, basic - continuing operations $ (2.46) $ (3.62)
Net loss per common share, diluted - continuing operations (2.46) (3.62)
Net loss per common share, basic - discontinued operations (0.19) (1.24)
Net loss per common share, diluted - discontinued operations $ (0.19) $ (1.24)
Weighted-average number of shares outstanding, basic 5,072,709 3,840,340
Weighted-average number of shares outstanding, diluted 5,072,709 3,840,340
Other comprehensive loss, net of tax    
Foreign currency translation adjustment from discontinued operations $ 119,473 $ 50,721
Other comprehensive loss (13,640,777) (20,983,922)
Comprehensive loss attributable to noncontrolling interest from discontinued operations (304,735) (2,394,100)
Comprehensive loss attributable to Qualigen Therapeutics, Inc. $ (13,336,042) $ (18,589,822)